Thyroid Function and Autoimmunity in Subfertility Women and Assisted Reproductive Therapy

Evaluation of Thyroid Function and Autoimmunity in Subfertility Women and Thyroid Hormone Levels in the First Trimester of Assisted Reproduction

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06394466

Enrollment

453

Registered

2024-05-01

Start date

2021-07-01

Completion date

2023-07-31

Last updated

2024-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Failure, Thyroid Diseases

Keywords

Anti mullerian hormone, Thyroid autoimmunity, Antithyroid antibodies, Infertility

Brief summary

The assessment of ovarian reserve is well established based on the dosage of anti-Mullerian hormone (AMH). The clinical applicability of detecting thyroid autoantibodies levels has been discussed as a potential marker of low-grade inflammation. There are no studies about the detection of these autoantibodies in infertile women. Our objective is to evaluate the association between ovarian reserve and thyroid function and its autoimmunity in infertile women seeking for assisted reproductive treatment (ART).Evaluation ot thyroid function in the first trimester in also be evaluated in women submitted to ART.

Detailed description

The assessment of ovarian reserve is well established based on the dosage of anti-Mullerian hormone (AMH). The clinical applicability of detecting thyroid autoantibodies levels has been discussed as a potential marker of low-grade inflammation. There are no studies about the detection of these autoantibodies in infertile women. Evaluation of TSH profile during ovarian stimulation in ART is also debated in literature with conflicting results. Our objective is to evaluate the association between ovarian reserve and thyroid function and its autoimmunity in infertile women seeking for assisted reproductive treatment (ART) and TSH profile during ovarian stimulation and during the first trimester.

Interventions

OTHERNon Applicable

Non Applicable

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Inclusion criteria were: women attended in the outpatient clinic with baseline exams before ART and during ovarian stimulation between July 2021 and July 2023

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
TSH levels during assisted reproductive therapy and first trimester	90 days	TSH, free and total thyroxine, and ioduria in the first trimester

Secondary

Measure	Time frame	Description
Association between AMH levels and detectable categories of TPO-Ab or Tg-Ab	30 days	AMH, TPO-Ab and Tg-Ab dosages
Correlation between AMH and TSH	30 days	AMH and TSH dosages

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026